FDA Shelves IVDMIA Final Guidelines in Order to Focus on Overall LDT Regulation

"It's possible that we will issue [an] IVDMIA guidance in the future but with this public meeting [scheduled for July], we are addressing LDTs at once in a public dialogue, instead of dealing with subset by subset," an FDA spokesperson told PGx Reporter.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.